Multiple Myeloma

Of the 4 patients with relapsed/refractory multiple myeloma who received KLN-1010, 1 complete response and 3 partial responses were achieved at varying levels of MRD sensitivity.

Phase 2 data support further evaluation of frontline BCMA/CD3 bispecific antibody combinations in phase 3 trials.

Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.

After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.

Results from the CAMMA 3 trial showed that subcutaneous cevostamab achieved a 52.0% ORR in BCMA-naive relapsed or refractory multiple myeloma.

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.

Gintemetostat plasma concentrations increased with dosing across all 9 dose levels tested in a phase 1 study.

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Giving cilta-cel in earlier lines of therapy leverages stronger baseline immune health and a more favorable TME to deliver enhanced clinical outcomes.

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.

A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.

The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this population with smoldering multiple myeloma.

Panelists discuss how patients relapsing shortly after BCMA CAR T-cell therapy should receive GPRC5D-targeted bispecifics rather than repeat BCMA therapies, given the evidence that prior BCMA exposure reduces efficacy of subsequent BCMA-directed treatments.

Belantamab mafodotin has been approved for multiple myeloma, despite the FDA’s ODAC voting against the treatment due to ocular toxicities.

Investigators are currently assessing the antibody-drug conjugate HDP-101 as part of a phase 1/2a study.

Panelists discuss how a triple class–exposed patient with comorbidities like COPD represents an ideal candidate for BCMA-directed bispecific therapy over CAR T-cell therapy due to the ability to titrate dosing and manage respiratory infection risks.